Antibody profiles in COVID‐19 convalescent plasma prepared with amotosalen/UVA pathogen reduction treatment

BACKGROUND: COVID‐19 convalescent plasma (CCP), from donors recovered from severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) infection, is one of the limited therapeutic options currently available for the treatment of critically ill patients with COVID‐19. There is growing evidence that...

Descripción completa

Detalles Bibliográficos
Autores principales: Bagri, Anil, de Assis, Rafael R., Tsai, Cheng‐Ting, Simmons, Graham, Mei, Zhen W., Von Goetz, Melissa, Gatmaitan, Michelle, Stone, Mars, Di Germanio, Clara, Martinelli, Rachel, Darst, Orsolya, Rioveros, Jowin, Robinson, Peter V., Ward, Dawn, Ziman, Alyssa, Seftel, David, Khan, Saahir, Busch, Michael P., Felgner, Philip L., Corash, Laurence M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Transfusion Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115453/
https://www.ncbi.nlm.nih.gov/pubmed/35128658
http://dx.doi.org/10.1111/trf.16819

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115453/
https://www.ncbi.nlm.nih.gov/pubmed/35128658
http://dx.doi.org/10.1111/trf.16819

Ejemplares similares